Displaying all 2 drugs
Nivolumab
Nivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region with the mutation S228P for additional stability and reduced variability. It was developed by Bristol Myers Squibb. Nivolumab was...
Approved
Matched Synonyms: … Nivolumab …
Matched Name: … Nivolumab …
Matched Description: … [L12129] It is also available in combination with [relatlimab] under the brand name Opdualag. ... [L12129] This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region ... [L12129] Nivolumab was granted FDA approval on 22 December 2014. …
Matched Categories: … nivolumab and relatlimab ... nivolumab ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Products: … NIVOLUMAB BMS ... Nivolumab Bms ... NIVOLUMAB BMS CONCENTRATE FOR SOLUTION FOR INFUSION 10MG/ML …
Matched Name: … Nivolumab …
Matched Description: … [L12129] It is also available in combination with [relatlimab] under the brand name Opdualag. ... [L12129] This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region ... [L12129] Nivolumab was granted FDA approval on 22 December 2014. …
Matched Categories: … nivolumab and relatlimab ... nivolumab ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Products: … NIVOLUMAB BMS ... Nivolumab Bms ... NIVOLUMAB BMS CONCENTRATE FOR SOLUTION FOR INFUSION 10MG/ML …
Relatlimab
Relatlimab is a human IgG4 monoclonal antibody and novel immune checkpoint inhibitor that targets lymphocyte activation gene-3 (LAG-3).[A246165,L41265] It was the first commercially developed anti-LAG-3 antibody, entering clinical trials in 2013, and has garnered interest in the treatment of a variety of cancers, including leukemia and melanoma. As immune checkpoint...
Approved
Investigational
Matched Synonyms: … Relatlimab …
Matched Name: … Relatlimab …
Matched Description: … [A246155] Relatlimab received FDA approval in March 2022, alongside the PD-1 inhibitor [nivolumab] ... Relatlimab is a human IgG4 monoclonal antibody and novel immune checkpoint inhibitor that targets lymphocyte ... have been trialed in combination with other checkpoint inhibitors - for example, PD-1 inhibitors like [nivolumab …
Matched Categories: … nivolumab and relatlimab ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Matched Name: … Relatlimab …
Matched Description: … [A246155] Relatlimab received FDA approval in March 2022, alongside the PD-1 inhibitor [nivolumab] ... Relatlimab is a human IgG4 monoclonal antibody and novel immune checkpoint inhibitor that targets lymphocyte ... have been trialed in combination with other checkpoint inhibitors - for example, PD-1 inhibitors like [nivolumab …
Matched Categories: … nivolumab and relatlimab ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Displaying all 2 drugs